NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer <u>and</u> to the FCA in Microsoft Word format if possible)

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ":			Greencare Capital plc			
1b. Please indication	1b. Please indicate if the issuer is a non-UK is				n "X" if appropriate)
Non-UK issuer						
2. Reason for the	e notification (plea	ase mark the a	appropr	iate box or boxes v	vith an "X")	
An acquisition or c	lisposal of voting rig	hts				
An acquisition or c	lisposal of financial	instruments				
An event changing	the breakdown of	voting rights				х
Other (please spe	cify) [⊪] :					
3. Details of pers	son subject to the	notification	obligat	ion ^{iv}		
Name	3. Details of person subject to the notification obligation № Name Eight Capital Partners Plc					
	f registered office (if	f applicable)				
4. Full name of s	shareholder(s) (if o	lifferent from 3	I 3.) ⊻			
Name						
City and country o	f registered office (if	f applicable)				
5. Date on which or reached vi:	the threshold wa	is crossed	3 July	2020		
6. Date on which (DD/MM/YYY):	issuer notified		13 July 2020			
7. Total position	s of person(s) sul	oject to the n	otificat	ion obligation		
	% of voting rights attached to shares (total of 8. A) % of voting through fina instrume (total of 8. 2)		incial nts	Total of both in % (8.A + 8.B)	Total number of vor rights of issuer vii	ting
Resulting situation on the date on which threshold was crossed or reached	17.3%	2.6%		19.9%	14,792,374	

Position of previous notification (if	21.2%	2.6%	23.8%	
applicable)				

A: Voting rights a	attached to shares			
Class/type of shares	Number of voting	rights ⁱ ×	% of voting rights	
Shares	Direct	Indirect	Direct	Indirect
ISIN code (if possible)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)	(Art 9 of Directive 2004/109/EC) (DTR5.1)	(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BJBYK814	2,560,000	384,000	17.3%	2.6%
SUBTOTAL 8. A	2,944,000		19	.9%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))				
Type of financial instrument	Expiration date ×	Exercise/ Conversion Period ^{xi}	Number of voting rights that may be acquired if the instrument is exercised/converted.	% of voting rights
Warrant	30/12/2024	30/12/2024	384,000	2.6%
		SUBTOTAL 8. B 1	384,000	2.6%

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))					
Type of financial instrument	Expiration date ×	Exercise/ Conversion Period ×i	Physical or cash settlement ^{xii}	Number of voting rights	% of voting rights

		SUBTOTAL 8.B.2	

9. Information in relation to the person subject to the notification obligation (please mark the				
applicable box with an "X")				
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii				
<u>Full</u> chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^{xiv} (please add additional rows as necessary)				
Name ×	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it e or is higher than notifiable thresh	the

10. In case of proxy voting, please identify:	
Name of the proxy holder	
The number and % of voting rights held	
The date until which the voting rights will be held	

11. Additional information **

Place of completion	AQSE, London
Date of completion	13/7/2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <u>rns@lseg.com</u> or visit <u>www.rns.com</u>.